TRX-518

• Description :

  TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR) . TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers[1].

• UNSPSC :

  12352203

• Target :

  TNF Receptor

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  98.58

• Smiles :

  [3H][R][X518]

• Molecular Weight :

  (145.26 kDa)

• References & Citations :

  [1]Zappasodi R, et al. Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial[J]. Cancer Research, 2017, 77 (13_Supplement) : CT018-CT018.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1